Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Fagron Compounding Services
WARNING LETTER
•Fagron Compounding Services•June 28, 2024

Fagron Compounding Services – FDA Warning Letter, Jun 28, 2024

Record Details

On December 19, 2024, the FDA issued Warning Letter #698861 to Fagron Compounding Services, LLC dba Fagron Sterile Services, an outsourcing facility registered under section 503B of the FDCA. The letter followed an inspection from June 18-28, 2024, which revealed serious deficiencies in sterile drug production and non-compliance with 503B conditions.

Violations included drug products failing to meet 503B labeling requirements, such as missing dosage form, established drug name, and active ingredient lists on product and container labels. These failures render the products ineligible for exemptions from FDA approval, adequate directions for use, and Drug Supply Chain Security Act requirements.

Furthermore, the FDA found adulterated drug products due to insanitary conditions and CGMP violations. Specific issues included inadequate product evaluation after microbial contamination in the ISO 5 aseptic area, production during construction without contamination controls, failure to investigate discrepancies (21 CFR 211.192), poor facility maintenance (21 CFR 211.56(a)), and lack of validated aseptic and sterilization procedures (21 CFR 211.113(b)).

The firm's drug products are considered unapproved new drugs and misbranded because they lack FDA approval and adequate directions for use for conditions not amenable to self-diagnosis.

While the FDA acknowledged the firm

Company
Fagron Compounding Services
Inspection date
June 28, 2024
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • F. Gail Bormel (F.)
View Company Profile

ID · 4f8f6bf4-aa3b-4792-ad0c-94ef43cad0c3

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 U.S.C. 353b21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 360eee-121 U.S.C. 353b(d)(4)21 U.S.C. 351(a)(2)(A)21 CFR 210

Full citation text and observation details available on the Dashboard.

Other documents for Fagron Compounding Services
  • 483 - 2025-08-08August 8, 2025
  • 483 - 2024-06-28June 28, 2024
  • 483 - 2022-03-24March 24, 2022
  • EIR - 2022-03-24March 24, 2022
  • 483 - 2019-06-21June 21, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Fagron Compounding Services
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.